ArticleBMC medical genomics2020
A random forest based biomarker discovery and power analysis framework for diagnostics research.
Article in BMC medical genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A priori sample size determination and power analysis in metabolic phenotyping and integrative metabolomics: an application framework based on a systematic review of literature.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
- A simulation-based comparison of Boruta, LASSO, and Elastic Net for variable selection in logistic regression, with an ovarian cancer miRNA application.BMC medical research methodology · 2026Article
- Accurate and noninvasive prostate cancer detection using plasma-derived extracellular vesicle RNA.FEBS open bio · 2026Article
- Optimized Mass Spectrometry to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles From Asymptomatic Tuberculosis Patients.The Journal of infectious diseases · 2026Article
- Age- and sex- related patterns in hematobiochemical and anthropometric parameters of Macaca monkeys.GeroScience · 2026Article
- Functional Depth Biomarkers Distinguish Lung Squamous Cell Carcinoma from Lung Adenocarcinoma.Research square · 2026Article
- Machine-learning algorithms to identify key practices contributing to variation in biosecurity levels on Japanese commercial swine farms.The Journal of veterinary medical science · 2026Article
- Sample size calculation for training ensemble machine learning models on health data.Patterns (New York, N.Y.) · 2026Article
- Machine learning-driven identification of virulence determinants in Borrelia burgdorferi associated with human dissemination.PLoS computational biology · 2026Article
- Multi-phase hybrid metabolomics framework identifies clinically applicable plasma signatures for early detection of gastric cancer.Nature communications · 2026Article
- Plasma acylcarnitine dysregulation associated with CPT1-mediated metabolism contributes to oral carcinogenesis.Scientific reports · 2026Article
- Benchmarking computational methods for multi-omics biomarker discovery in cancer.Briefings in bioinformatics · 2026Article
- Dietary Modulation of Gut Microbiota and Metabolome Shapes Growth Performance inAnimals : an open access journal from MDPI · 2026Article
- A Five-Plasma Protein-Based Algorithm for Predicting Incident CKD in Type 2 Diabetes.Journal of the American Society of Nephrology : JASN · 2026Article
- A multi-omics analysis of gut bacteriome, virome, and serum metabolome in bipolar depression.Npj mental health research · 2026Article
- Sharing approaches in predictive genomics across animals, plants and humans.Nature genetics · 2026Review
- Article
- Artificial Intelligence in Nephrology-State of the Art on Theoretical Background, Molecular Applications, and Clinical Interpretation.International journal of molecular sciences · 2026Review
- Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications.CNS neuroscience & therapeutics · 2026Article
- Development and validation of a machine learning-based diagnostic model for obstructive coronary artery disease in hypertensive patients using composite inflammatory and lipid markers.Frontiers in cardiovascular medicine · 2026Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBiomarker identification is one of the major and important goal of functional genomics and translational medicine studies. Large scale -omics data are increasingly being accumulated and can provide vital means for the identification of biomarkers for the early diagnosis of complex disease and/or for advanced patient/diseases stratification. These tasks are clearly interlinked, and it is essential that an unbiased and stable methodology is applied in order to address them. Although, recently, many, primarily machine learning based, biomarker identification approaches have been developed, the exploration of potential associations between biomarker identification and the design of future experiments remains a challenge.
methodsIn this study, using both simulated and published experimentally derived datasets, we assessed the performance of several state-of-the-art Random Forest (RF) based decision approaches, namely the Boruta method, the permutation based feature selection without correction method, the permutation based feature selection with correction method, and the backward elimination based feature selection method. Moreover, we conducted a power analysis to estimate the number of samples required for potential future studies.
resultsWe present a number of different RF based stable feature selection methods and compare their performances using simulated, as well as published, experimentally derived, datasets. Across all of the scenarios considered, we found the Boruta method to be the most stable methodology, whilst the Permutation (Raw) approach offered the largest number of relevant features, when allowed to stabilise over a number of iterations. Finally, we developed and made available a web interface ( https://joelarkman.shinyapps.io/PowerTools/ ) to streamline power calculations thereby aiding the design of potential future studies within a translational medicine context.
conclusionsWe developed a RF-based biomarker discovery framework and provide a web interface for our framework, termed PowerTools, that caters the design of appropriate and cost-effective subsequent future omics study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.